Climb Bio (CLYM) announced the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Altschuller served as the Chief Financial Officer of Cerevel Therapeutics until its $8.7B acquisition by AbbVie (ABBV) and Chief Financial Officer of ImmunoGen
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM:
- Climb Bio price target raised to $8 from $7 at BTIG
- Climb Bio Unveils Promising Preclinical Data for CLYM116
- Climb Bio announces CLYM116 preclinical data
- Climb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunity
- Climb Bio: Strong Clinical Execution and Promising Pipeline Make It a Compelling Investment Opportunity